The Phase 1 cancer trial involved 6 patients with cancer metastatic to the liver or with recurrent liver cancer.
According to Provectus Pharma, the primary objective of the study is to determine the safety and tolerability of a single intralesional injection of PV-10 in patients with cancer of the liver.
Provectus Pharma CEO Craig Dees said preliminary results for PV-10 as a treatment for liver cancer are very encouraging as they show the treatment was generally well-tolerated, with substantial evidence of efficacy.
"We believe PV-10’s ability to selectively target and destroy cancer cells without harming surrounding healthy tissue make it a potentially attractive therapy for cancers of the liver, which can be very serious and difficult to treat if they cannot be fully removed through surgery," Dees said.